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Summary
Overdiagnosis is the diagnosis of an abnormality that is not
associated with a substantial health hazard and that patients
have no benefit to be aware of. It is neither a misdiagnosis
(diagnostic error), nor a false positive result (positive test
in the absence of a real abnormality). It mainly results from
screening, use of increasingly sensitive diagnostic tests, in-
cidental findings on routine examinations, and widening
diagnostic criteria to define a condition requiring an in-
tervention. The blurring boundaries between risk and dis-
ease, physicians’ fear of missing a diagnosis and patients’
need for reassurance are further causes of overdiagnosis.
Overdiagnosis often implies procedures to confirm or ex-
clude the presence of the condition and is by definition as-
sociated with useless treatments and interventions, generat-
ing harm and costs without any benefit. Overdiagnosis also
diverts healthcare professionals from caring about other
health issues. Preventing overdiagnosis requires increasing
awareness of healthcare professionals and patients about its
occurrence, the avoidance of unnecessary and untargeted
diagnostic tests, and the avoidance of screening without
demonstrated benefits. Furthermore, accounting systemat-
ically for the harms and benefits of screening and diagnost-
ic tests and determining risk factor thresholds based on the
expected absolute risk reduction would also help prevent
overdiagnosis.
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Introduction
Traditionally, a diagnosis is based on clinical symptoms
and signs, and a patient’s past medical history. The devel-
opment of preventive medicine and diagnostic technolo-
gies, in a context of a predominance of chronic conditions
with a long pre-clinical phase, have changed the diagnostic
process, expanding the possibilities of interventions across
asymptomatic individuals and blurring the boundaries
between health, risk and disease [1].
An unwanted effect of these developments is overdiagnos-
is, defined as the diagnosis of an abnormality that is not as-
sociated with a substantial health hazard [2–5] and that pa-
tients have no benefit to be aware of [6]. Over-diagnosis is
neither a misdiagnosis (diagnostic error), nor a false posit-
ive result (positive test in the absence of a real abnormal-
ity). Nevertheless, it leads to overtreatment that provides,
by definition, no benefit but that can cause harm and induce
costs.
Our goal is to comprehensively review the causes of over-
diagnosis (table 1) and to propose interventions to prevent
its occurrence (table 2).
Literature search
We sought for publications related to overdiagnosis in the
Medline database via PubMed (1950 to March 2014).
Search terms were “overdiagnosis” OR “overdetection”.
Some 1603 potential citations were identified and screened.
We selected high quality general reviews about overdia-
gnosis and original research studies assessing the existence
and the frequency of overdiagnosis, in all domains of medi-
cine and public health. A similar search was conducted
in Google scholar to find additional publications. We also
conducted a hand search of bibliographies of all relevant
articles. Additionally, websites dedicated to the issue of
overdiagnosis were searched for.
Causes of overdiagnosis
Overdiagnosis can directly result from screening tests, use
of increasingly sensitive diagnostic tests, incidental find-
ings on routine examinations, and widening diagnostic cri-
Table 1: Causes of overdiagnosis [2–5].
Proximal causes:
Screening
Increasing sensitivity of diagnostic tests
Incidental findings (following laboratory or radiological examinations,
genetic tests, etc.)
Widening diagnosis criteria to diagnose a condition requiring an
intervention
Distal causes:
Blurring boundaries between risk and disease
Physician's fear of missing a diagnosis and fear of litigation
Patient's need of reassurance
Financial incentives
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teria to define a condition requiring an intervention (table
1) [2–5]. Indirectly, the blurring boundaries between risk
and diseases, the fear of missing a diagnosis and the pa-
tients’ need for reassurance are further causes of overdia-
gnosis.
Screening and overdiagnosis of
cancers
Screening is a major source of cancer overdiagnosis. An
overdiagnosed cancer is defined as a tumour whose histo-
logy indicates a cancerous lesion but which will not evolve
to become symptomatic or lethal. These tumours constitute
a reservoir of potentially detectable cancers. The size of
this reservoir is estimated by post mortem histological ex-
amination of tissue in people who have not suffered from or
have not died of such a cancer. For example, 30% to 70%
of men aged over 60 have asymptomatic prostatic cancer-
ous lesions [2].
Screening causes a shift in tumour grade or histology to-
ward more indolent cancers [7, 8]. Therefore, cancer
screenings tend to detect malignancies that are growing
more slowly on average than cancers clinically diagnosed.
This is the source of the “length-time bias” (or “prognostic
bias”) that must be taken into account in the evaluation of
screening. In extreme cases, screening can detect cancer
that would have never become symptomatic before the
death of the screened individual: these cases are overdia-
gnosed.
Prostate cancer
Since 2012, the U.S. Preventive Services Task Force
(USPSTF) recommends not to perform routine screening of
prostate cancer by the determination of prostate- specific
antigen (PSA) [9]. In view of the frequent side effects
(urinary incontinence, erectile dysfunction) due to treat-
ment and of unclear benefits, the balance between risks and
harms has been considered unfavourable by the USPSTF
[9]. A recent Cochrane review concluded that screening
had no effect on mortality from prostate cancer [10].
There is strong evidence that screening for prostate cancer
by PSA is an important source of overdiagnosis. Indeed,
prostate cancer is heterogeneous and many tumours found
by screening grow slowly and are not life threatening [9,
11] and PSA is unable to distinguish aggressive cancers
requiring intervention from indolent cancers [12]. Further-
more, the large increases in the incidence of prostate cancer
in US and several European countries are compatible with
overdiagnosis. The estimates are uncertain but between
17% and 66% of prostate cancers detected by PSA screen-
ing would be overdiagnosed [9, 11]. The probability of
overdiagnosis is higher in older men, having a relatively
low Gleason score and a relatively low level of PSA at dia-
gnosis [13]. Overdiagnosis and overtreatment are among
the reasons cited by the USPSTF to recommend against
PSA screening for prostate cancer [9].
Breast cancer
The USPSTF recommends routine screening for breast
cancer with mammography every two years for women
50 to 74 years [14]. Randomised studies have shown that
routine screening reduces mortality from breast cancer by
about 20% [15]. The net benefit of screening is directly
related to absolute baseline risk of breast cancer and in-
creases with age [16]. Although to a lesser extent compared
with prostate cancer, some cases of breast cancer dis-
covered following mammography are overdiagnosed
[15–18]. In a recent review of randomised trials, it was es-
timated that 19% of cases detected by screening every 3
years beginning at the age of 50 years were overdiagnosed
[15]. However, there were large uncertainties on the fre-
quency of overdiagnosis estimates, ranging from 0% up
Table 2: Intervention to prevent overdiagnosis [5].
Method Example
Avoid certain diagnostic tests or screening Systematic screening for prostate cancer by PSA measurement [9]
Scan of the entire body to search for non-specific abnormalities
See also Choosing Wisely Initiative (www.choosingwisely.org/) [28]
Reduce the frequency of screening test Breast cancer screening every 2 years instead of every year [18]
Targeted screening Screening for familial hypercholesterolaemia in children with a typical
family history
Lung cancer screening in heavy smokers
Inform the patient of the possibility of overdiagnosis and the balance
between the benefits and risks of screening; to help make an informed
and shared decision [51]
Screening for breast cancer with mammography: mortality benefit vs
harms of overdiagnosis [14–16]
Anticipate the consequences of abnormalities discovered following a
diagnostic test or screening
Renal mass discovered on an abdominal CT: plan monitoring, additional
tests, and treatment if necessary
Screening with combined diagnostic and prognostic tools (biomarker,
personalised medicine) [43, 45, 53]
Test for cancer susceptibility biomarkers; tailor prevention and
screening according to the risk of cancer [43, 45, 53]
Prognosis estimation to decide whether or not to screen and treat Cardiovascular risk estimation based on age or on the basis of a clinical
score (e.g., Framingham)
When assessing a risk factor, consider the absolute risk of disease
associated with this factor and expected absolute risk reduction through
intervention or treatment
The relative increase in the cardiovascular risk associated with high
cholesterol is similar in old people and in young people compared to
same age people with low cholesterol. However, the absolute increase
in the risk and the benefits of treatment are low in young people with
high cholesterol
Avoid conflicts of interests in guideline panel committees Mandatory declaration of conflict of interest and exclusion of experts
with health industry financial ties
Change terminology for conditions with a high probability of indolence to
prevent overtreatment [53]
Cancer vs indolent lesions of epithelial origin (IDLE) [53]
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to 36% of invasive breast cancers diagnosed during the
screening period [14].
Overdiagnosis of other cancers
Overdiagnosis could explain in part the increase in the in-
cidence of melanoma [19], as well as lung [20, 21], kidney,
and thyroid cancers [22, 23], which are often discovered
incidentally following radiological examinations (CT scan,
MRI, ultrasound) [3].
Increasing sensitivityof diagnostic
tests and incidental findings
The use of increasingly sensitive radiological diagnostic
tests is a source of overdiagnosis for several conditions,
including pulmonary embolism [24, 25]. Due to the high
mortality risk, pulmonary embolism is a diagnosis that
physicians do not want to miss. Therefore, the increasing
sensitivity of diagnostic tools, such as multi- detector CT-
scans, is clinically appealing. However, this leads to an in-
creased detection of less severe cases of pulmonary embol-
ism (e.g., sub-segmental) for which the benefit of antico-
agulation is doubtful [24, 25].
In the US, the incidence of pulmonary embolism was stable
between 1993 and 1998 but increased from 62 to 112 cases
per 100,000 persons between 1998 and 2006, a period char-
acterised by the growing use of more sensitive multi-de-
tector CT-scans. Despite the increased number of detected
pulmonary embolism, mortality from this condition has de-
creased only slightly since 1993 [24]. A pattern of massive
increase in the incidence without significant change in
mortality is compatible with overdiagnosis. Indeed, there is
a true reservoir of potentially detectable pulmonary embol-
isms [26, 27].
The increasing use of diagnostic imaging, in conjunction
with an increasing sensitivity, leads to frequent incidental
findings of abnormalities whose clinical hazard is uncertain
but for which follow-up tests are required and treatment
are, eventually, prescribed [28]. A classical example is the
adrenal incidentaloma found on abdominal CT-scans. A re-
port of 25 autopsy studies estimates the prevalence of an
incidental adrenal mass to be 6% and up to 4% of abdom-
inal CTs reveal an unexpected adrenal mass [29]. The great
majority of adrenal incidentalomas are benign adenomas.
However, because these incidentalomas can also be a se-
creting adenoma, pheochromocytoma, adrenocortical car-
cinoma, or metastatic carcinoma, they require additional
diagnostic procedures and a potential increase of overdia-
gnosed and overtreated cases.
Whole-body radiological imaging is a major potential
source of overdiagnosis. For example, among 1,192 per-
sons with no particular health problem and having under-
gone a whole-body CT-scan, abnormalities were found in
86% of patients, with an average of 2.8 abnormalities per
patient [30]. Genetic tests are also a source for incidental
findings and overdiagnosis [31].
Widening diagnosis criteria
A more subtle form of overdiagnosis is related to the lower-
ing of thresholds, for example of blood pressure, blood
cholesterol or blood glucose, to define conditions requiring
treatment [32, 33]. Lowering thresholds are justified by
the continuous association between the variables of interest
and the risk of diseases, such as between the level of systol-
ic blood pressure and the risk of cardiovascular diseases.
Due to this continuity in the risk, it is theoretically useful
to decrease blood pressure at any level in order to decrease
the risk of blood pressure related diseases.
However, the relationship between a given risk factor and
the risk of disease is generally log- linear [34, 35]. Thus, a
pressure reduction of 10 mm Hg is associated with a great-
er absolute risk reduction if the blood pressure is initially at
160 mm Hg than if it is at 140 mm Hg: the higher the blood
pressure, the greater the absolute risk reduction. Below a
given threshold, the absolute benefit of treatment becomes
minimal and insufficient in regards to the potential harm
[35]. This is a situation of overdiagnosis and overtreatment.
Lowering thresholds also leads to a substantial increase in
the number of cases treated for high blood pressure, high
blood cholesterol, diabetes or their precursors, such as pre-
hypertension or pre-diabetes [35]. Widening of diagnostic
thresholds, and the resulting overdiagnosis, leads to an epi-
demic of diagnoses [3, 36]. To limit the risk of overdia-
gnosis, it is key to consider the absolute risk of disease be-
cause the higher the absolute risk, the lower the probability
of overdiagnosis, and this is true at any level of risk factors.
More generally, the blurring boundaries between risk and
disease contribute to causing overdiagnosis [37]. Indeed,
being at risk of diseases is increasingly confounded with
the disease itself, and it is true in particular for chronic dis-
eases such as diabetes or various cancers.
Physician’s fear of missing a diagnosis
and patients’ need for reassurance
Another cause of overdiagnosis is the physician’s fear of
missing a diagnosis and the patient’s need for reassurance.
The fear of missing a diagnosis is at the heart of the physi-
cian ethos, and as such, is difficult to fight. The fear of lit-
igation also exists because in some jurisdictions there is a
risk of litigation when a test is not done, but not when a
test is done even if it results in the identification of indol-
ent abnormalities [38]. Financial incentives for physicians
and from pharmaceutical and diagnostic industries are also
causing overdiagnosis [39]. More broadly, societal “more
is better” attitudes and blind beliefs in new technologies
are major drivers for more testing, and hence more overdia-
gnosis.
Methods to estimate the frequency of
overdiagnosis
There is no consensus on how to estimate the frequency
of overdiagnosis. The excess incidence method is based on
the comparisons of cancer incidence in screened and un-
screened populations. Thus, if there is no overdiagnosis,
the cumulative-incidence should be equal in both popu-
lations with a follow-up extended over a few years after
the end of screening period; in case of overdiagnosis, the
cumulative-incidence will be larger in the screened popula-
tion, due to the excess cases detected (fig. 1) [40]. A stand-
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ard calculation to estimate the percentage of overdiagnosed
cases is:
(incidence in screened population – incidence in un-
screened population) / incidence in unscreened population.
One difficulty is to compare screened and unscreened pop-
ulations having the same underlying risk of cancer, ideally
using randomised trials data. If observational data are used,
it is necessary to adjust for cancer risk factors and to ac-
count for the actual degree of participation to screening, the
time interval between screening tests (overdiagnosis tends
to be more frequent with shorter intervals [18]), the sens-
itivity of the screening test, and the lead-time [41]. Anoth-
er method is based on the modelling of the lead-times bias
[42]. This method requires information on the incidence of
cancer without screening, and on the pattern of screening
dissemination [39].
Over-diagnosis due to cancer screening can also be as-
sessed by the analyses of secular trends in cancer stages.
In theory, following the introduction of screening, the in-
cidence of cancers initially increases and, after a few years,
return to the pre-screening level (fig. 1) [42, 43]. More spe-
cifically, a few years after the introduction of screening,
the number of cases diagnosed at an early stage should
have increased and the number of cases at an advanced
stage should have, ideally, decreased, with the total number
of cases unchanged [42, 43]. In case of overdiagnosis,
however, once screening is implemented, the incidence re-
mains above the pre-screening level [42, 43].
Prevention of overdiagnosis
A case of overdiagnosis would be identifiable if the person
was not treated for the detected abnormality, never suffered
from this abnormality, and eventually died of an unrelated
cause [2]. However, once an abnormality is identified, it is
almost impossible -and often unethical- not to investigate
Figure 1
Panel A) Following the implementation of cancer screening,
assuming no true change in the frequency of cancer, the observed
incidence will initially increase before reaching again, in the long
term, the incidence observed in the pre-screening era. In case of
overdiagnosis, in the long term, the incidence does not return to
pre-screening level due to the excess cases detected [43]; Panel B)
Comparing cumulative incidence of screened and unscreened
population can demonstrate overdiagnosis due to a screening test
done regularly during a given period of life, e.g., mammography for
breast cancer. During the period of screening, the cumulative
incidence is higher with screening than without screening. Few
years after the end of screening period, the cumulative incidence in
the screened population reach the cumulative incidence in the
unscreened population if there is no overdiagnosis. In case of
overdiagnosis, the cumulative incidence remains higher [40, 43,
45].
and not to treat the patient even if there is a high probability
of overdiagnosis.
Nevertheless, overdiagnosis can be prevented (table 2). In-
creasing awareness of healthcare professionals and patients
about overdiagnosis and avoiding unnecessary diagnostic
tests, useless routine examinations, and inefficient screen-
ing should be advocated. One major difficulty is that many
screening tests are very popular [44] and even when a given
screening test has been shown to be inefficient, it will of-
ten continue to be proposed and performed [16]. Recently,
the American Board of Internal Medicine has launched the
“Choosing Wisely” initiative (www.choosingwisely.org/)
with the aim of identifying useless tests with a potential
of overdiagnosis [28]. The Swiss Society of Internal Medi-
cine has launched a similar campaign, Smarter Medicine
(www.smartermedicine.ch).
Targeted screening also reduces the risk of overdiagnosis.
Screening with combined diagnostic and prognostic tools
(e.g., using biomarkers before screening to assess the sus-
ceptibility of the persons to develop the disease and for
the aggressiveness of the disease detected) could help tar-
get the persons with the greatest probability of benefits and
the lowest risk of overdiagnosis [43, 45]. Unfortunately,
there is no convincing pre-clinical prognostic tool to de-
termine the evolution of most at-risk or chronic conditions.
Research devoted to personalised medicine should try to
help design targeted screening strategy.
An intervention on risk factors such as elevated blood pres-
sure is justified only by its ability to substantially reduce
the associated absolute risk of disease. It is therefore essen-
tial to educate physicians and patients to frame risk in ab-
solute terms rather than in relative terms. More generally,
before doing a test, it is necessary to estimate the absolute
risk associated with the condition and to do the test only if
it is possible to reduce this risk substantially. Furthermore,
overdiagnosis can occur with underdiagnosis in the same
population. For instance, while some patients at low cardi-
ovascular risk are treated, some high-risk patients are not
treated. This may be due to the fact that the decision to treat
is based on the level of the risk factor itself (e.g., cholester-
ol level), and not on the associated absolute cardiovascular
risk [46]. Prevention of overdiagnosis should not be done at
the cost of increasing under-diagnosis and under-treatment.
The financial interests of diagnostic and pharmaceutical in-
dustries are also a source of overdiagnosis [39]. Recom-
mendations for diagnostic procedures or for the definitions
of conditions requiring treatment should be elaborated by
experts who have no ties with these industries. A recent
study showed that many panel members of guidelines pro-
posing a widening of the definition of common conditions
had financial ties with the healthcare industry [47]. Further-
more, none of these guidelines reported potentials harm of
such a widening.
Once an abnormality is detected, the goal must be to pre-
vent overtreatment. Tools like prognostic scores can help
distinguishing abnormalities associated with a substantial
risk and requiring treatment from indolent ones. For condi-
tions with a high risk of overdiagnosis, a watchful waiting
strategy should be considered. For example, under certain
conditions, patients with a prostate cancer of low grade and
low volume discovered by screening may be initially fol-
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lowed without treatment [48]. However, these patients may
choose to be treated quickly because of an underlying fear
that the risk of cancer-related death may have been under-
estimated [48]. Further, physicians may fear an underestim-
ation of risk and anticipate that they might regret not hav-
ing recommended intervention [49].
Physicians should also discuss with their patients the be-
nefits and harm associated with a diagnostic or screening
test, including the risk of overdiagnosis [50]. Significance
of harm (including overdiagnosis) and benefits associated
with a given test depends on individuals’ value and pref-
erences. Ideally, the goal is to reach a shared decision [51]
and balanced information on the probabilities of harm and
benefits, accounting for uncertainties, has to be provided to
the patients [16, 18, 52]. Some patients will accept the risk
of overdiagnosis, and other will not.
Finally, changing terminology for some conditions based
on their degree of health risk could help prevent overtreat-
ment. Minimal-risk, low-grade, and non-invasive breast
and prostate lesions could be better labelled “indolent le-
sion of epithelial origin” (IDLE) rather than “cancer”, this
term implying a high probability of death without treatment
[45, 53]. Ductal intraepithelial neoplasia (DIN) and pro-
state intraepithial neoplasia (PIN) have been proposed [45,
53]. Some indolent thyroid cancers have been named mi-
cropapillary lesions of indolent course (microPLICs) [54].
Changes in nomenclature for low risk cancers would also
help patients and physicians choose active surveillance.
Conclusion
Overdiagnosis is mainly the consequence of a technology-
driven medicine that aims to improve patient outcomes
by detecting disease in its earliest form. Overdiagnosis is
of growing relevance in population dominated by chronic
conditions having long pre-clinical stage. Although early
detection has been shown to be beneficial for several con-
ditions, it also increases the probability of finding insigni-
ficant abnormalities, whose treatment is not associated with
any benefit but can harm the patient. Moreover, overdia-
gnosis diverts healthcare professionals from caring about
other health issues and generates costs. The increase in
healthcare costs, the over- and underutilisation of some
care, the debates about the effectiveness of several screen-
ing, and the growing role of patients in medical decisions
require concern about overdiagnosis.
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Figure 1
Panel A) Following the implementation of cancer screening, assuming no true change in the frequency of cancer, the observed incidence will
initially increase before reaching again, in the long term, the incidence observed in the pre-screening era. In case of over-diagnosis, in the long
term, the incidence does not return to pre-screening level due to the excess cases detected [43]; Panel B) Comparing cumulative incidence of
screened and unscreened population can demonstrate over-diagnosis due to a screening test done regularly during a given period of life, e.g.,
mammography for breast cancer. During the period of screening, the cumulative incidence is higher with screening than without screening. Few
years after the end of screening period, the cumulative incidence in the screened population reach the cumulative incidence in the unscreened
population if there is no over-diagnosis. In case of over-diagnosis, the cumulative incidence remains higher [40, 43, 45].
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